Literature DB >> 23070752

Surgical resection of endolymphatic sac tumors in von Hippel-Lindau disease: findings, results, and indications.

H Jeffrey Kim1, Marygrace Hagan, John A Butman, Martin Baggenstos, Carmen Brewer, Christopher Zalewski, W Marston Linehan, Russell R Lonser.   

Abstract

OBJECTIVES/HYPOTHESIS: To define the surgical treatment and outcomes of von Hippel-Lindau (VHL) disease-associated endolymphatic sac tumors (ELSTs), we analyzed consecutive VHL patients who underwent ELST resection. STUDY
DESIGN: Retrospective investigation of consecutive VHL patients who underwent resection of ELSTs at a clinical research center between 1999 and 2010.
METHODS: Analysis of serial clinical examinations, audiograms, imaging studies, and operative findings were analyzed.
RESULTS: Thirty-one consecutive patients with ELSTs (15 males, 16 females) underwent resection of 33 tumors (mean follow-up, 49.9 ± 48.0 months; range, 1.0-116 months). One patient had bilateral ELST resections and one patient underwent reoperation for recurrence. Mean age at surgery was 38.2 ± 10.2 years (range, 12-67 years). Whereas 29 ears (88%) had direct radiographic evidence of an ELST, four ears (12%) did not. Mean tumor size was 1.3 ± 1.1 cm (range, 0.2-5.2 cm). Whereas two patients (two ears, 6%) were asymptomatic, 29 patients (31 ears, 94% of ears) had associated audiovestibular symptoms, including sensorineural hearing loss (28 ears, 84%), tinnitus (24 ears,73%), and vertigo (21 patients, 68%). Postoperatively, hearing was stabilized (27) or improved (three) in 97% of 31 ears. Complete tumor resection was achieved in 30 ears (91% of 33 ears). Complications included cerebrospinal fluid leak in two ears (6%) and transient lower cranial nerve palsy in one ear (3%).
CONCLUSIONS: Surgical resection of ELSTs can be performed with hearing preservation and a reduction in audiovestibular dysfunction. Early surgical resection can prevent or decrease disabling audiovestibular symptoms, enhance the opportunity for complete resection, and preserve hearing.
Copyright © 2012 The American Laryngological, Rhinological, and Otological Society, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 23070752      PMCID: PMC7560989          DOI: 10.1002/lary.23646

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  26 in total

1.  VHL gene inactivation in an endolymphatic sac tumor associated with von Hippel-Lindau disease.

Authors:  A O Vortmeyer; D Choo; S Pack; E Oldfield; Z Zhuang
Journal:  Neurology       Date:  2000-08-08       Impact factor: 9.910

2.  Surgical outcomes in patients with endolymphatic sac tumors.

Authors:  Marlan R Hansen; William M Luxford
Journal:  Laryngoscope       Date:  2004-08       Impact factor: 3.325

3.  Is cochlear implantation possible after acoustic tumor removal?

Authors:  A Belal
Journal:  Otol Neurotol       Date:  2001-07       Impact factor: 2.311

4.  Tumors of the endolymphatic sac in patients with von Hippel-Lindau disease: implications for their natural history, diagnosis, and treatment.

Authors:  H Jeffrey Kim; John A Butman; Carmen Brewer; Christopher Zalewski; Alexander O Vortmeyer; Gladys Glenn; Edward H Oldfield; Russell R Lonser
Journal:  J Neurosurg       Date:  2005-03       Impact factor: 5.115

5.  Endolymphatic sac tumor (aggressive papillary tumor of middle ear and temporal bone): sine qua non radiology-pathology and the University of Texas MD Anderson Cancer Center experience.

Authors:  Diana Bell; Paul Gidley; Nicholas Levine; Gregory N Fuller
Journal:  Ann Diagn Pathol       Date:  2010-12-16       Impact factor: 2.090

6.  Differential expression of transthyretin in papillary tumors of the endolymphatic sac and choroid plexus.

Authors:  C A Megerian; B Z Pilch; A K Bhan; M J McKenna
Journal:  Laryngoscope       Date:  1997-02       Impact factor: 3.325

7.  Aggressive papillary tumor of middle ear/temporal bone and adnexal papillary cystadenoma. Manifestations of von Hippel-Lindau disease.

Authors:  M J Gaffey; S E Mills; J C Boyd
Journal:  Am J Surg Pathol       Date:  1994-12       Impact factor: 6.394

8.  Von Hippel-Lindau disease: a genetic study.

Authors:  E R Maher; L Iselius; J R Yates; M Littler; C Benjamin; R Harris; J Sampson; A Williams; M A Ferguson-Smith; N Morton
Journal:  J Med Genet       Date:  1991-07       Impact factor: 6.318

Review 9.  von Hippel-Lindau disease.

Authors:  Russell R Lonser; Gladys M Glenn; McClellan Walther; Emily Y Chew; Steven K Libutti; W Marston Linehan; Edward H Oldfield
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

10.  Mechanisms of morbid hearing loss associated with tumors of the endolymphatic sac in von Hippel-Lindau disease.

Authors:  John A Butman; H Jeffrey Kim; Martin Baggenstos; Joshua M Ammerman; James Dambrosia; Athos Patsalides; Nicholas J Patronas; Edward H Oldfield; Russell R Lonser
Journal:  JAMA       Date:  2007-07-04       Impact factor: 56.272

View more
  14 in total

1.  The endolymphatic sac tumor: challenges in the eradication of a localized disease.

Authors:  Vittoria Sykopetrites; Gianluca Piras; Annalisa Giannuzzi; Antonio Caruso; Abdelkader Taibah; Mario Sanna
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-09-05       Impact factor: 2.503

2.  Endolymphatic Sac Tumor Screening and Diagnosis in von Hippel-Lindau Disease: A Consensus Statement.

Authors:  Gautam U Mehta; H Jeffery Kim; Paul W Gidley; Anthony B Daniels; Mia E Miller; Gregory P Lekovic; John A Butman; Russell R Lonser
Journal:  J Neurol Surg B Skull Base       Date:  2021-04-08

3.  Sporadic endolymphatic sac tumor--a diagnostic and therapeutic challenge.

Authors:  Julian Künzel; Abbas Agaimy; Joachim Hornung; Michael Lell; Oliver Ganslandt; Sabine Semrau; Johannes Zenk
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

Review 4.  Von Hippel-Lindau Disease.

Authors:  Jennifer J Findeis-Hosey; Kelly Q McMahon; Sarah K Findeis
Journal:  J Pediatr Genet       Date:  2016-04-04

5.  Treatment of endolymphatic sac tumour (Papillary adenocarcinoma) of the temporal bone.

Authors:  Arturo Mario Poletti; Siba Prasad Dubey; Giovanni Colombo; Giovanni Cugini; Antonio Mazzoni
Journal:  Rep Pract Oncol Radiother       Date:  2015-07-30

Review 6.  Von Hippel-Lindau disease.

Authors:  Prashant Chittiboina; Russell R Lonser
Journal:  Handb Clin Neurol       Date:  2015

7.  Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone.

Authors:  Shigeru Kawabata; M Christine Hollander; Jeeva P Munasinghe; Lauren R Brinster; José R Mercado-Matos; Jie Li; Lucia Regales; William Pao; Pasi A Jänne; Kwok-Kin Wong; John A Butman; Russell R Lonser; Marlan R Hansen; Richard K Gurgel; Alexander O Vortmeyer; Phillip A Dennis
Journal:  Oncotarget       Date:  2015-05-10

Review 8.  A Review of Von Hippel-Lindau Syndrome.

Authors:  Neha Varshney; Amanuel A Kebede; Harry Owusu-Dapaah; Jason Lather; Manu Kaushik; Jasneet S Bhullar
Journal:  J Kidney Cancer VHL       Date:  2017-08-02

9.  Synchronous Presentation of Rare Brain Tumors in Von Hippel-Lindau Syndrome.

Authors:  Mariachiara Lodi; Antonio Marrazzo; Antonella Cacchione; Marina Macchiaiolo; Antonino Romanzo; Luciano Mastronardi; Francesca Diomedi-Camassei; Alessia Carboni; Andrea Carai; Carlo Gandolfo; Lidia Monti; Angela Mastronuzzi; Giovanna Stefania Colafati
Journal:  Diagnostics (Basel)       Date:  2021-05-31

Review 10.  Personalized Medicine for Nervous System Manifestations of von Hippel-Lindau Disease.

Authors:  Victoria Schunemann; Kristin Huntoon; Russell R Lonser
Journal:  Front Surg       Date:  2016-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.